Latest news
Otsuka’s Voyxact stabilised kidney function at two years in Phase III IgAN trial - YahooYahoo · Tue, 04 Aug 2026 15:19:30 GMTSibeprenlimab (Voyxact) Stabilizes Kidney Function in IgAN - HCPLiveHCPLive · Tue, 04 Aug 2026 15:04:13 GMTOtsuka Unveils Phase 3 VOYXACT Results for IgA Nephropathy Treatment - World Business OutlookWorld Business Outlook · Tue, 04 Aug 2026 05:40:13 GMTOtsuka's Voyxact Halts Kidney Function Decline In Phase 3 IgAN Trial, Strengthening FDA Approval Bid - londoninsider.co.uklondoninsider.co.uk · Mon, 03 Aug 2026 23:18:29 GMTOtsuka’s VOYXACT Phase 3 Data Show Sustained Kidney Function Stabilization in IgA Nephropathy - TipRanksTipRanks · Mon, 03 Aug 2026 21:56:51 GMTIn a first, Otsuka’s Voyxact stabilizes IgAN patients’ kidney function decline to normal levels - Fierce PharmaFierce Pharma · Mon, 03 Aug 2026 21:00:00 GMTOtsuka Unveils Unprecedented Phase 3 VISIONARY Two-Year eGFR Results Demonstrating VOYXACT® (sibeprenlimab-szsi) Stabilizes Kidney Function Decline to Baseline Physiologic Rate, Fundamentally Altering Disease Progression in IgA Nephropathy - Business WireBusiness Wire · Mon, 03 Aug 2026 21:00:00 GMT